WEBINAR: iPSC-based 3D Microtissues and their Applications in Drug Discovery

iPSC-derived 3D models create a more complex environment to improve sensitivity and accuracy for therapeutic screening. However, they often require high cell numbers along with complex equipment, limiting their suitability for high throughput screening.

Together with the LUMC, Ncardia has established strategies to generate scalable 3D cardiac microtissues in an automated manner, as well as procedures to evaluate the compound responses and facilitate their use in high-throughput screenings. These microtissues are made from a tri-cellular combination of iPSC-derived cardiomyocytes, endothelial cells, and fibroblasts, which enhances cardiac maturation and improves drug response predictions.

In this webinar we will present the challenges and advantages of generating 3D cardiac microtissues and their application in high-throughput assays for cardiac safety assessment and disease modeling.